XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting ( n the second half of 2007. CUSTOM II ...)

XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting

n the second half of 2007.

CUSTOM II webcast and slide presentation

XTENT will host a webcast, slide presentation and telebriefing to review the CUSTOM II data Tuesday, May 22 at 2:00p.m. EDT (at 8:00p.m. CEST). The teleconference and slide presentation can be accessed via the investor relations section of the Company's website at http://investor.xtentinc.com/events.cfm or by calling 800-361-0912 (from the U.S.), 913-981-5559 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call. The webcast will be archived on the website for a minimum of three months, and can be accessed at the investor relations portion of the company's website at http://investor.xtentinc.com

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's ability to initiate its U.S. pivotal trial in the second ha
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:

(Date:8/14/2008)...a., Aug. 14 /- The Clinical Trials,Bo...ucating physicians,clinical coordinators, clinica...l trial. It will be held in Boca Raton at the Boca...ators, clinical coordinators, monitors and,other i...ow to incorporate,clinical trials into a practice,...

(Date:8/14/2008)...pment to begin in late 2008 or in early 2009 -, S...-- Nuvelo, Inc.,(Nasdaq: NUVO ) today announced p... trial of NU172, demonstrating that the direct thr...ticoagulation with a rapid,return toward baseline ...rofile., "NU172 has the potential to address many...

(Date:8/13/2008)...RNewswire-FirstCall/ -- As biotechnology,pharmace...ove clinical,trials beyond their own borders to ot...pe and South America, complicated regulatory envir...ess, according to an analysis by,Aon Corporation (...provides,those companies a visual representation o...

(Date:8/13/2008)...hid Pharma partners with Diakron, MORRIS PLAINS, ...als,Inc. announced today the signing of an exclus...oral anticoagulant drug candidate discovered and,d...& Co. Inc. Under the,terms of the agreement, Diakr...proved, market and distribute the compound worldwi...

Breaking Medicine Technology:Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2 Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3 Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4 Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc. 2 Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 5926 1 Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 5926 2 Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 5926 3 Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 5926 4 Eleven Going on 70 3A SCAN Health Plan Helps Fifth Graders Understand Aging Through First Ever Senior Sensitivity Training for Kids 21542 1 Eleven Going on 70 3A SCAN Health Plan Helps Fifth Graders Understand Aging Through First Ever Senior Sensitivity Training for Kids 21542 2 Tubbs Jones Addresses Health Disparities Issue During Hearing 21537 1 Tubbs Jones Addresses Health Disparities Issue During Hearing 21537 2 Three peat 3A Nurture 28R 29 Strikes Gold Again at NeoCon 21535 1 Three peat 3A Nurture 28R 29 Strikes Gold Again at NeoCon 21535 2

[0] Clinical Trials Bootcamp Announces Inaugural Meeting [0] Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 [0] Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders [0] Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.

... Merck,Serono S.A. (virt-x: SEO) announced today t...hase III development for the treatment,of Parkinso...essor,Fabrizio Stocchi at the American Academy of ...etts, USA. These data are from a,6-month (24 weeks...nternational trial. , "These data are promising fo...

...ational Cancer,Institute , , , , , , BAS... today in,the Journal of the National Cancer Insti...n to improve overall survival in patients,with lym...1 The,review further stated that the improvement i... with mantle cell lymphoma, a rare,aggressive for...

Other Medicine Technology:Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 2 Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 3 Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 4 Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting 5 MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen 2 MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen 3 MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen 4

Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting MabThera Significantly Increases Survival of Lymphoma Patients,Regardless of Chemotherapy Regimen

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...

(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...

(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...

(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...

[0] Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use [0] Medicare Advantage Plans Struggle to Comply With New Federal Law [0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History

...and have risen 36 percent since last year, local p...to-borne disease swept the region. The outbreak ... than 21,000 since the beginning of the year, the ... newspaper reported, quoting figures from the heal...

...has helped cure a teenager Scot of severe asthma. ...he disease were such that he had to give up sports...other Janet, a community matron, had read somewher... playing wind instruments to people with breathing...

...Shekhar today died in the Apollo Hospital of the c...cer of the plasma cell and was admitted in May af...kar, a MA from the Allahabad Universtiy, is surviv...born on July 1, 1927. He was a Member of Parliame...

...onstrated outside the seat of the Polish governmen... pitched camp in front of the building in a two-w...lway workers and miners from Poland's southern Sil...reading, "We want a decent living, like lawmakers"...

Other Medicine News:Health News:Trade Unionists Join Polish Nurses' Protest 2

Dengue Fever Cases Up 36 Percent in Thailand: Report Bagpipe Cured Scot Teen of His Asthma Former Prime Minister Chandra Shekhar Died of Cancer Trade Unionists Join Polish Nurses' Protest

...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...

Medicine Products:

Rapid Plasma Reagin (RPR with Reflex to Fluorescent Treponemal Antibody, IgG Confirmation Rapamune Raji Cell Immune Complex Assay RA

( n the second half of 2007. CUSTOM II ...)XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting,Health